Sales Guidance Cut: On October 23, 2025, Integer lowered its full-year sales guidance to between $1.840 billion and $1.854 billion, below expectations, resulting in a 32.3% drop in stock price that day, significantly harming investors.
Weak Product Sales: The company anticipates declines in sales for three new products in 2026, particularly two electrophysiology devices, indicating challenges in market adoption and product rollout.
Market Competition Missteps: The lawsuit alleges that Integer overstated its competitive position in the electrophysiology market and failed to disclose deteriorating sales, misleading investors about the company's prospects.
Investor Losses: Following this news, Integer's stock plummeted from $108.11 to $73.89, leading to substantial financial losses for investors and prompting legal accountability for the company's management.
ITGR
$73.7816+Infinity%1D
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 91.75 USD with a low forecast of 69.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 91.75 USD with a low forecast of 69.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 73.900
Low
69.00
Averages
91.75
High
140.00
Current: 73.900
Low
69.00
Averages
91.75
High
140.00
Citi
Neutral
maintain
$69 -> $75
2025-12-11
Reason
Citi
Price Target
$69 -> $75
2025-12-11
maintain
Neutral
Reason
Citi raised the firm's price target on Integer to $75 from $69 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.
Truist
Buy
downgrade
$88 -> $86
2025-11-24
Reason
Truist
Price Target
$88 -> $86
2025-11-24
downgrade
Buy
Reason
Truist lowered the firm's price target on Integer to $86 from $88 and keeps a Buy rating on the shares. Following the firm's meeting with the company CEO, Truist continues to believe that it could take a few quarters before investors underwrite a re-acceleration in the second half of FY26, the analyst tells investors in a research note.
Citi
Neutral
downgrade
$77 -> $69
2025-11-03
Reason
Citi
Price Target
$77 -> $69
2025-11-03
downgrade
Neutral
Reason
Citi lowered the firm's price target on Integer to $69 from $77 and keeps a Neutral rating on the shares.
Benchmark
Robert Wasserman
Buy
to
Hold
downgrade
2025-10-24
Reason
Benchmark
Robert Wasserman
Price Target
2025-10-24
downgrade
Buy
to
Hold
Reason
Benchmark analyst Robert Wasserman downgraded Integer to Hold from Buy with no price target after management lowered guidance for FY25 and "perhaps most damaging," initiated a flat-to-lower outlook for FY26 due to reduced demand for three products that the company manufactures. The firm is lowering its rating until the company can return to growth mode, the analyst tells investors.
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
